163 related articles for article (PubMed ID: 20708609)
1. A sensitive assay to measure biomarker glycosylation demonstrates increased fucosylation of prostate specific antigen (PSA) in patients with prostate cancer compared with benign prostatic hyperplasia.
Dwek MV; Jenks A; Leathem AJ
Clin Chim Acta; 2010 Dec; 411(23-24):1935-9. PubMed ID: 20708609
[TBL] [Abstract][Full Text] [Related]
2. Glycosylation of urinary prostate-specific antigen in benign hyperplasia and cancer: assessment by lectin-binding patterns.
Janković MM; Kosanović MM
Clin Biochem; 2005 Jan; 38(1):58-65. PubMed ID: 15607318
[TBL] [Abstract][Full Text] [Related]
3. Characterization and determination of the complex between prostate-specific antigen and alpha 1-protease inhibitor in benign and malignant prostatic diseases.
Zhang WM; Finne P; Leinonen J; Stenman UH
Scand J Clin Lab Invest Suppl; 2000; 233():51-8. PubMed ID: 11317942
[TBL] [Abstract][Full Text] [Related]
4. alpha1,2-Fucosylated and beta-N-acetylgalactosaminylated prostate-specific antigen as an efficient marker of prostatic cancer.
Fukushima K; Satoh T; Baba S; Yamashita K
Glycobiology; 2010 Jan; 20(4):452-60. PubMed ID: 20008118
[TBL] [Abstract][Full Text] [Related]
5. Different glycan structures in prostate-specific antigen from prostate cancer sera in relation to seminal plasma PSA.
Tabarés G; Radcliffe CM; Barrabés S; Ramírez M; Aleixandre RN; Hoesel W; Dwek RA; Rudd PM; Peracaula R; de Llorens R
Glycobiology; 2006 Feb; 16(2):132-45. PubMed ID: 16177264
[TBL] [Abstract][Full Text] [Related]
6. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Lümmen G; Wernli M; Wiefelspütz J; Graber SF; Goepel M; Huber A; Tscholl R
Cancer; 1998 Dec; 83(12):2540-7. PubMed ID: 9874461
[TBL] [Abstract][Full Text] [Related]
7. Multigene methylation analysis for detection and staging of prostate cancer.
Enokida H; Shiina H; Urakami S; Igawa M; Ogishima T; Li LC; Kawahara M; Nakagawa M; Kane CJ; Carroll PR; Dahiya R
Clin Cancer Res; 2005 Sep; 11(18):6582-8. PubMed ID: 16166436
[TBL] [Abstract][Full Text] [Related]
8. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.
Becker C; Piironen T; Pettersson K; Björk T; Wojno KJ; Oesterling JE; Lilja H
J Urol; 2000 Jan; 163(1):311-6. PubMed ID: 10604382
[TBL] [Abstract][Full Text] [Related]
9. Core fucosylation and alpha2-3 sialylation in serum N-glycome is significantly increased in prostate cancer comparing to benign prostate hyperplasia.
Saldova R; Fan Y; Fitzpatrick JM; Watson RW; Rudd PM
Glycobiology; 2011 Feb; 21(2):195-205. PubMed ID: 20861084
[TBL] [Abstract][Full Text] [Related]
10. Carbohydrate structure and differential binding of prostate specific antigen to Maackia amurensis lectin between prostate cancer and benign prostate hypertrophy.
Ohyama C; Hosono M; Nitta K; Oh-eda M; Yoshikawa K; Habuchi T; Arai Y; Fukuda M
Glycobiology; 2004 Aug; 14(8):671-9. PubMed ID: 15044396
[TBL] [Abstract][Full Text] [Related]
11. Additional use of [-2] precursor prostate-specific antigen and "benign" PSA at diagnosis in screen-detected prostate cancer.
de Vries SH; Raaijmakers R; Blijenberg BG; Mikolajczyk SD; Rittenhouse HG; Schröder FH
Urology; 2005 May; 65(5):926-30. PubMed ID: 15882725
[TBL] [Abstract][Full Text] [Related]
12. [Clinical assessment of free serum prostate specific antigen (PSA)].
Chautard D; Daver A; Bali B; Dardari J; Debras B; Colls P; Soret JY
Prog Urol; 1996 Jun; 6(3):368-74. PubMed ID: 8763691
[TBL] [Abstract][Full Text] [Related]
13. Benign prostatic hyperplasia-associated free prostate-specific antigen improves detection of prostate cancer in an artificial neural network.
Stephan C; Cammann H; Deger S; Schrader M; Meyer HA; Miller K; Lein M; Jung K
Urology; 2009 Oct; 74(4):873-7. PubMed ID: 19476981
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of prostate-specific antigen and prostatic acid phosphatase in untreated prostatic carcinoma and benign prostatic hyperplasia.
Bogdanowicz JF; Bentvelsen FM; Oosterom R; Schroeder FH
Scand J Urol Nephrol Suppl; 1991; 138():97-103. PubMed ID: 1723815
[TBL] [Abstract][Full Text] [Related]
15. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS
Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
[TBL] [Abstract][Full Text] [Related]
16. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
Ho PJ; Baxter RC
Clin Endocrinol (Oxf); 1997 Mar; 46(3):333-42. PubMed ID: 9156044
[TBL] [Abstract][Full Text] [Related]
17. Detection of prostate-specific antigen coupled to immunoglobulin M in prostate cancer patients.
Beneduce L; Prayer-Galetti T; Giustinian AM; Gallotta A; Betto G; Pagano F; Fassina G
Cancer Detect Prev; 2007; 31(5):402-7. PubMed ID: 18035503
[TBL] [Abstract][Full Text] [Related]
18. Clinical usefulness of serum antip53 antibodies for prostate cancer detection: a comparative study with prostate specific antigen parameters.
Suzuki H; Akakura K; Igarashi T; Ueda T; Ito H; Watanabe M; Nomura F; Ochiai T; Shimada H
J Urol; 2004 Jan; 171(1):182-6. PubMed ID: 14665872
[TBL] [Abstract][Full Text] [Related]
19. Role of free to total prostate specific antigen ratio in serum in the diagnosis of prostatic enlargement.
Bhuiyan AK; Kibria SA; Subhan SS
Bangladesh Med Res Counc Bull; 2004 Aug; 30(2):51-9. PubMed ID: 15813483
[TBL] [Abstract][Full Text] [Related]
20. Serum-to-urinary prostate-specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer.
Hillenbrand M; Bastian M; Steiner M; Zingler C; Müller M; Wolff JM; Seiter H; Schuff-Werner P
Anticancer Res; 2000; 20(6D):4995-6. PubMed ID: 11326656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]